By restoring the DC maturation and enhancing their capacity to prime CD8+ T cells, this approach reprograms the TME of EGFR‐mutant NSCLC, fostering more effective anti‐tumor immune responses than the traditional drug delivery method. This evidence concerns the gene EGFR and non-small cell lung carcinoma.